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Objective
To evaluate disease activity, management with pharma-
cological therapy and the impact on functional capacity
and quality of life of psoriatic arthritis in Spain.
Methods
Cross-sectional, multicenter, national survey. The fol-
lowing data were collected: age, sex, type of psoriasis,
swollen and tender joint counts (SJ 44/TJ 46), ESR
(mm/1hora), CRP (mg/dL), DAS28, Psoriasis Global
Assessment (PGA), Physician Global Assessment
(PhyGA), Patient Global Assessment (PatGA), pharma-
cological therapy taken (AINEs, glucocorticoids,
DAMARDs, and anti-TNFalfa therapy), Visual Analogue
Scale (VAS) of pain, Disease impact as measured by
VAS in the personal, occupational and social spheres,
Health Assessment Questionnaire (HAQ) and Dermatol-
ogy Life Quality Index (DLQI).
Results
214 patients with psoriatic arthritis fulfilling CASPAR
criteria from 54 Spanish rheumatology outpatient clinics
were included. Fifty-six per cent were male and the age
was (mean (95%CI)) 52 years (50.1-53.8). Patient had
the following clinical activity TJC: 3.2 (2.6-3.7); SJC: 2.4
(2-2.9); ESR: 20.6 (18.4-22.8) mm/1 h; CRP: 5.3 (3.7-6.8)
mg/dL; DAS28: 3.10 (2.9-3.3); PhyGA: 24.7 (21.4-27.9);
PatGA: 29.2 (25.2-33.2); VAS pain: 29.7 (25.5-38.8).
Twenty four percent of patients had a moderate-severe
extent of PsA as measured by PGA.
Of 173 patients from whom DAS28 was available, 38%
were en remission (DAS28<2.6); 23% had low activity
(DAS28>2.6<3.2) and 39% had moderate or high activity
(DAS28>3.2). 98.6% of patients were taken drugs for
treatment of psoriatic arthritis: 21% oral glucocorticoids
(<5 mg of prednisolone), 86.2% DMARDs (96% metho-
trexate and/or leflunomide) and 26.2% anti-TNFalfa
therapies.
Disease impact measured by VAS in the personal
sphere was higher in females than in males (31.2 (25-
37.4) vs 22.1 (16.7-27.5); p<0.03). The global HAQ was
0.61 (0.52-0.7), being significantly higher en females (0.84
(0.71-0.97) vs 0.4 (0.31-0.54);p<000001). Global DLQ was
3.5 (2.8-4.2), with youngest patients (18-29 years) report-
ing greater involvement (18% indicated severe o very
severe effects, with scores between 11 and 30)).
Conclusions
This observational national survey on psoriatic arthritis
is the first study trying to reflect the treatment and state
of patients with psoriatic arthritis in Spain. Globally it
suggest that although most patients are treated with
DMARDs and one quarter with anti-TNFalfa blockers,
around 40% exhibit moderate-high joint disease activity
and around 25% moderate-high skin involvement.
Furthermore, although the impact of the disease on
functional capacity and psoriasis-related quality of life is
globally mild-moderate, the group constituted by
females and people of <30 years suffers a greater impact,
suggesting the need of intensify the treatment of their
joint and skin involvement.
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